SightGlass Vision, Inc.
14
4
12
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Choroidal Response to Novel Spectacle Lens to Control Myopia Progression
Role: lead
CYPRESS Efficacy and Safety Study Extension
Role: lead
Myopia Control Spectacle Lens Cessation Study
Role: lead
Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness
Role: lead
Spectacle Lens Visual Acuity Assessments Study
Role: lead
Lag of Accommodation With DOT Spectacle Lenses
Role: lead
Assessment of DOT Spectacles in Chinese Children
Role: lead
Control of Myopia Using Novel Spectacle Lens Designs
Role: lead
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
Role: lead
Children's Viewing Behavior
Role: lead
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
Role: lead
Assessment of DOT Spectacles in Chinese Children Extension
Role: lead
Myopia Assessment of Two Manufacturing Processes
Role: lead
Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast
Role: lead
All 14 trials loaded